Pedersen S S, Pressler T, Høiby N, Bentzon M W, Koch C
J Antimicrob Chemother. 1985 Nov;16(5):629-35. doi: 10.1093/jac/16.5.629.
Ten patients with cystic fibrosis and chronic broncho-pulmonary Pseudomonas aeruginosa infection received 45 mg imipenem/cilastatin per kg body weight/day, intravenously for two weeks. The treatment was safe with only minor side effects and clinical parameters improved considerably during therapy. In all patients resistance of Ps. aeruginosa to imipenem developed in the second week of treatment; in seven patients the therapy selected for a resistant strain and in three resistance developed in the original strain. The resistance persisted after cessation of treatment and thus the clinical usefulness of imipenem/cilastatin as monotherapy in CF-patients with Ps. aeruginosa seems to be limited.
十名患有囊性纤维化且伴有慢性支气管肺部铜绿假单胞菌感染的患者，接受了每公斤体重每日45毫克亚胺培南/西司他丁静脉注射，为期两周。治疗安全，仅有轻微副作用，且治疗期间临床参数有显著改善。在所有患者中，铜绿假单胞菌对亚胺培南的耐药性在治疗的第二周出现；七名患者的治疗选择了耐药菌株，三名患者的原始菌株产生了耐药性。停药后耐药性依然存在，因此亚胺培南/西司他丁作为单一疗法对患有铜绿假单胞菌的囊性纤维化患者的临床效用似乎有限。
